Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Accumulated Expenses (2021 - 2024)

HCW Biologics (HCWB) has disclosed Accumulated Expenses for 4 consecutive years, with $90000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Accumulated Expenses rose 11.11% year-over-year to $90000.0, compared with a TTM value of $90000.0 through Sep 2024, up 11.11%, and an annual FY2022 reading of $134000.0, changed N/A over the prior year.
  • Accumulated Expenses was $90000.0 for Q3 2024 at HCW Biologics, down from $152000.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $229000.0 in Q1 2022 and bottomed at $53000.0 in Q1 2023.
  • Average Accumulated Expenses over 4 years is $126491.6, with a median of $115000.0 recorded in 2023.
  • The sharpest move saw Accumulated Expenses plummeted 76.86% in 2023, then soared 92.45% in 2024.
  • Year by year, Accumulated Expenses stood at $214408.0 in 2021, then plummeted by 37.5% to $134000.0 in 2022, then tumbled by 39.55% to $81000.0 in 2023, then increased by 11.11% to $90000.0 in 2024.
  • Business Quant data shows Accumulated Expenses for HCWB at $90000.0 in Q3 2024, $152000.0 in Q2 2024, and $102000.0 in Q1 2024.